Trial · NCT05752279
Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis
NCT05752279, Phase 3, Completed, The George Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis. Trials, record NCT05752279. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05752279
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis
- NCT number
- NCT05752279
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 547 participants, actual
- Lead sponsor
- The George Institute
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Plasma-Lyte 148, 0.9% sodium chloride
- First posted
- 2023-03-02
- Last updated
- 2026-10-05
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hospital free days (HFD) up to day-28 after study enrolment | from time of enrolment to 28 days | Number of hospital free days from time of hospital discharge |
| Secondary | ICU free days up to 28 days after study enrolment | 28 days after enrolment | Number of ICU free days from time of ICU discharge |
| Secondary | ICU and hospital readmissions up to 28 days after study enrolment | 28 days after enrolment | Number of days free from ICU and hospital from time of hospital discharge |
| Secondary | Acute kidney injury assessed by comparing serum creatinine using Kidney Disease: Improving Global Outcomes (KDIGO) criteria | 28 days after enrolment | injury assessed by comparing change in serum creatinine using Kidney Disease: Improving Global Outcomes (KDIGO) criteria |
| Secondary | Episodes of post-study enrolment decrease in Glasgow Coma Scale (GCS) by more than 2 in the first 24 hours | first 24 hours from enrolment | decrease in Glasgow Coma Score by more than 2 points |
| Secondary | Time to resolution of ketosis | from time of enrolment to day 28 | resolution of acidosis |
| Secondary | Cumulative insulin dosage in the first 48 hours | first 48 hours from time of enrolment | Total amount of insulin given to the patient from enrolment to 48 hours |
| Secondary | Duration of IV insulin infusion | from time of enrolment to day 28 | Total amount of IV insulin given to the patient from time of enrolment to day 28 |
| Secondary | Cumulative potassium replacement | from time of enrolment to day 28 | Total amount of potassium given to the patient from time of enrolment to day 28 |
| Other | Cost-effectiveness | from time of enrolment to day 28 | Calculation of the incremental cost-effectiveness ratios |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05752279
GET https://conductscience.org/api/trials/v1/NCT05752279/registered